Lupin subsidiary settles US antitrust case with Humana for $30 Million

The litigation involved multiple civil lawsuits alleging anti-competitive practices and violations of federal

Glenmark Pharmaceuticals reached $37.75 million settlement in antitrust litigation in US

Glenmark USA is named in multiple antitrust and consumer protection lawsuits, including class actions, consolidated in the Eastern District of Pennsylvania, U.S

Natco Pharma and Breckenridge dismissed from antitrust lawsuit

Glenmark Pharmaceuticals USA reaches antitrust settlement with DOJ

The company has entered into a three-year Deferred Prosecution Agreement

Merck moves to seal $53-a-share takeover of Terns Pharmaceuticals

The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701

Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million

Moderna teams up with Recordati to commercialize rare disease therapy

European Commission fines Alchem for participating in API cartel

The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle

AbbVie to acquire Capstan Therapeutics for $2.1 billion

Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region